About Vascular Biogenics (NASDAQ:VBLT)
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VBLT
CUSIPN/A
Phone972-3634-6450
Debt
Debt-to-Equity RatioN/A
Current Ratio7.73%
Quick Ratio7.73%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.86 million
Price / Sales4.75
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-10,130,000.00
Net MarginsN/A
Return on Equity-25.48%
Return on Assets-21.97%
Miscellaneous
Employees34
Outstanding Shares29,900,000
Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions
What is Vascular Biogenics' stock symbol?
Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."
How were Vascular Biogenics' earnings last quarter?
Vascular Biogenics (NASDAQ:VBLT) issued its quarterly earnings data on Thursday, March, 15th. The biopharmaceutical company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.19. The biopharmaceutical company had revenue of $13.86 million for the quarter. View Vascular Biogenics' Earnings History.
When is Vascular Biogenics' next earnings date?
What price target have analysts set for VBLT?
4 Wall Street analysts have issued 12-month price targets for Vascular Biogenics' shares. Their predictions range from $3.00 to $4.00. On average, they expect Vascular Biogenics' share price to reach $3.3333 in the next twelve months. View Analyst Ratings for Vascular Biogenics.
Are investors shorting Vascular Biogenics?
Vascular Biogenics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 651,389 shares, a decrease of 49.3% from the February 28th total of 1,285,337 shares. Based on an average daily trading volume, of 1,175,897 shares, the days-to-cover ratio is currently 0.6 days. Currently, 5.1% of the shares of the company are sold short.
Who are some of Vascular Biogenics' key competitors?
Some companies that are related to Vascular Biogenics include Athersys (ATHX), Synlogic (SYBX), Kindred Biosciences (KIN), Syndax Pharmaceuticals (SNDX), Mustang Bio (MBIO), Ovid Therapeutics (OVID), Neos Therapeutics (NEOS), Chimerix (CMRX), resTORbio (TORC), Bellicum Pharmaceuticals (BLCM), Aratana Therapeutics (PETX), Ocular Therapeutix (OCUL), ArQule (ARQL), Vital Therapies (VTL) and Fortress Biotech (FBIO).
Who are Vascular Biogenics' key executives?
Vascular Biogenics' management team includes the folowing people:
- Prof. Dror Harats, CEO & Director (Age 61)
- Mr. Amos Ron, CFO, Principal Accounting Officer & Company Sec. (Age 63)
- Dr. Erez Feige Ph.D., M.B.A., VP of Bus. Operations (Age 44)
- Dr. Eyal Breitbart Ph.D., VP of Research & Operations (Age 51)
- Dr. Naamit Sher Ph.D., VP of Drug Devel. & Regulatory (Age 64)
Has Vascular Biogenics been receiving favorable news coverage?
Media stories about VBLT stock have been trending positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vascular Biogenics earned a daily sentiment score of 0.37 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 48.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Vascular Biogenics?
Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vascular Biogenics' stock price today?
One share of VBLT stock can currently be purchased for approximately $2.20.
How big of a company is Vascular Biogenics?
Vascular Biogenics has a market capitalization of $65.77 million and generates $13.86 million in revenue each year. The biopharmaceutical company earns $-10,130,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Vascular Biogenics employs 34 workers across the globe.
How can I contact Vascular Biogenics?
Vascular Biogenics' mailing address is 6 JONATHAN NETANYAHU ST., OR YEHUDA L3, 60376. The biopharmaceutical company can be reached via phone at 972-3634-6450 or via email at [email protected]
MarketBeat Community Rating for Vascular Biogenics (VBLT)
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vascular Biogenics (NASDAQ:VBLT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Vascular Biogenics in the last 12 months. Their average twelve-month price target is $3.3333, suggesting that the stock has a possible upside of 51.52%. The high price target for VBLT is $4.00 and the low price target for VBLT is $3.00. There are currently 4 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.00 | 2.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.3333 | $3.3333 | $15.6667 | $14.75 |
| Price Target Upside: | 51.52% upside | 41.84% upside | 125.42% upside | 145.83% upside |
Vascular Biogenics (NASDAQ:VBLT) Consensus Price Target History
Vascular Biogenics (NASDAQ:VBLT) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Vascular Biogenics (NASDAQ:VBLT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vascular Biogenics (NASDAQ VBLT) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 5.82%
Vascular Biogenics (NASDAQ VBLT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Vascular Biogenics (NASDAQ VBLT) News Headlines
| Source: |
|
Vascular Biogenics (NASDAQ:VBLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vascular Biogenics (NASDAQ:VBLT) Income Statement, Balance Sheet and Cash Flow Statement
Vascular Biogenics (NASDAQ VBLT) Stock Chart for Thursday, April, 26, 2018
Loading chart…
